CF Trading Volume Surges 77% to 2.91 Billion, Ranks 364th in Market

On July 16, 2025, CF's trading volume reached 2.91 billion, marking a 77.07% increase from the previous day, ranking 364th in the day's market. CF, a leading biotechnology company, has seen its stock price decline by 3.44% over the past three days, with a cumulative drop of 5.74%.

Prime Medicine, a biotechnology company focused on genetic therapies, has received an additional $24 million in funding from the Cystic Fibrosis Foundation. This funding is aimed at accelerating the development of Prime Editors, a technology designed to permanently correct cystic fibrosis-related lung disease. The investment builds on an initial agreement made in January 2024 and reflects the foundation's interest in Prime Editing as a potentially curative approach for CF. Prime Editing can correct a wide range of genetic mutations, with the initial focus on the G542X mutation, one of the most prevalent CF-causing mutations. The company will also continue to advance hotspot and PASSIGE-based approaches for other mutations.

Prime Medicine's CEO, Allan Reine, expressed gratitude for the continued support from the CF Foundation, highlighting the transformative potential of Prime Editing therapy for people with CF. The funding will be provided in two tranches, subject to certain closing conditions and scientific milestones, with the first tranche including a $6 million equity investment in Prime Medicine. The CF Foundation's investment underscores the significant unmet need for a one-time, potentially curative treatment that can address the underlying genetic cause of CF across diverse genotypes.